

Press Release:

November 28, 2016 Taikisha Ltd.

A new model is introduced in the lineup of DRYDECO mobby: indoor-installable, mobile hydrogen peroxide-based decontamination systems - To realize the manufacture of reliable, safe, and fine-quality pharmaceuticals

Taikisha Ltd. (representative director/president: Satoru Kamiyama; head office: Shinjuku-ku, Tokyo, Japan) developed an indoor installation model of the compact, mobile hydrogen peroxide-based decontamination system <u>DRYDECO mobby</u>, and released in July 2016. Now available in three models, central (stationary), outdoor installation, and indoor installation, DRYDECO mobby is a flexible solution coming in a wider variety of equipment types and having various applications.

Background/Process

Aseptic pharmaceutical production facilities, animal experiment facilities, virus/genetically modified DNA experiment facilities, etc. are obligated to be internally decontaminated, and the revision of the Ordinance on Prevention of Hazards Due to Specified Chemical Substances (March 2008) imposed stricter control on formaldehyde that had been used for indoor decontamination.

Under those circumstances, Taikisha developed the indoor decontamination^{*1} system HYPER DRYDECO, which is capable of decontaminating rooms safely and certainly with hydrogen peroxide in place of formalin fumigation, in collaboration with Takeda Pharmaceutical Company Limited in 2010, and the compact, mobile decontamination system <u>DRYDECO mobby</u> (outdoor model) in 2011.

This year, Taikisha developed and released the indoor model of DRYDECO mobby (50 m^3 capacity and 300 m^3 capacity) in response to customers' needs. We strived to make this indoor model easier to use and reduce its installation costs.

^{*1}Decontamination: Reducing the bacterial count to a certain predetermined level in the field of medicine.

Main Features of the Product

- 1) Installation of a flexible, inexpensive decontamination system
 - The indoor model can be used in various environments even if their scales, decontamination frequencies, and decontamination levels are different. It can also save costs because it no longer requires fixed equipment.
- 2) Decontamination concentration control with a gas densitometer

The integral hydrogen peroxide densitometer (electrochemical type) helps to stably control the indoor concentration of hydrogen peroxide gas.

 Condensation-free decontamination with hydrogen peroxide in a dry environment Since the effect of corrosion can be minimized, construction materials, production devices, etc. suffer little damage.

4) Excellent workability and operability

The small type (50 m³ capacity) measures 390 (W) \times 515 (L) \times 800 (H) mm (weight: 55 kg), and the large type (300 m³ capacity) measures 560 (W) \times 950 (L) \times 1500 (H) mm (weight: 135 kg). Both types are compact in size and, what is more, achieve excellent workability and operability.

Future

To manufacture reliable, safe, and fine-quality pharmaceuticals, pharmaceutical companies operating global-scale businesses are required under PIC/S^{*2}, which is a scheme for achieving international consistency in inspections of pharmaceuticals, to establish strict production and quality assurance systems. The requirement of not using formaldehyde is also related closely to a series of PIC/S actions.

Taikisha has catered to customers' needs for stopping the use of formaldehyde through the development and sale of compact, mobile hydrogen peroxide-based decontamination systems. And we desire to make a greater contribution so that each pharmaceutical company can manufacture reliable, safe, and fine-quality pharmaceuticals.

Taikisha's systems are also introduced for the decontamination of safety cabinets used for cell culturing in the field of regenerative medicine, which has been achieving notable progress these past few years. We are determined to promote the sales of our systems more actively.


^{*2}PIC/S: It stands for Pharmaceutical Inspection Convention and Pharmaceutical Co-operation Scheme. PIC/S is a joint scheme intended to ensure international consistency in inspections of pharmaceuticals to manufacture reliable, safe, and fine-quality pharmaceuticals. Japan acceded to PIC/S in July 2014.



Small type (50 m³ capacity)



Large type (300 m³ capacity)



Contact for inquiries from the press about this press release Taikisha Ltd. Investor Relations Section, Administrative Management Headquarters: TEL: 03-5338-5052 FAX: 03-5338-5195 E-mail: mailmast@taikisha.co.jp